Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP849897.RAp4VmK2S3U9fRc-iFXHNMEf64QoLe_4dJqsOdM4dTk2w130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP849897.RAp4VmK2S3U9fRc-iFXHNMEf64QoLe_4dJqsOdM4dTk2w130_assertion type Assertion NP849897.RAp4VmK2S3U9fRc-iFXHNMEf64QoLe_4dJqsOdM4dTk2w130_head.
- NP849897.RAp4VmK2S3U9fRc-iFXHNMEf64QoLe_4dJqsOdM4dTk2w130_assertion description "[FLT-3 inhibitors account for a notable exception since they have resulted effective in vivo in AML with mutated, but not over expressed, FLT-3.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP849897.RAp4VmK2S3U9fRc-iFXHNMEf64QoLe_4dJqsOdM4dTk2w130_provenance.
- NP849897.RAp4VmK2S3U9fRc-iFXHNMEf64QoLe_4dJqsOdM4dTk2w130_assertion evidence source_evidence_literature NP849897.RAp4VmK2S3U9fRc-iFXHNMEf64QoLe_4dJqsOdM4dTk2w130_provenance.
- NP849897.RAp4VmK2S3U9fRc-iFXHNMEf64QoLe_4dJqsOdM4dTk2w130_assertion SIO_000772 21044004 NP849897.RAp4VmK2S3U9fRc-iFXHNMEf64QoLe_4dJqsOdM4dTk2w130_provenance.
- NP849897.RAp4VmK2S3U9fRc-iFXHNMEf64QoLe_4dJqsOdM4dTk2w130_assertion wasDerivedFrom befree-2016 NP849897.RAp4VmK2S3U9fRc-iFXHNMEf64QoLe_4dJqsOdM4dTk2w130_provenance.
- NP849897.RAp4VmK2S3U9fRc-iFXHNMEf64QoLe_4dJqsOdM4dTk2w130_assertion wasGeneratedBy ECO_0000203 NP849897.RAp4VmK2S3U9fRc-iFXHNMEf64QoLe_4dJqsOdM4dTk2w130_provenance.